Toyocamycin
Cat.No:IT3110 Solarbio
CAS:606-58-6
Molecular Formula:C12H13N5O4
Molecular Weight:291.26
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
ER Stress >
ToyocamycinCAS:606-58-6
Molecular Formula:C12H13N5O4
Molecular Weight:291.26
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 606-58-6 |
Name | Toyocamycin |
Molecular Formula | C12H13N5O4 |
Molecular Weight | 291.26 |
Solubility | Soluble in DMSO |
Purity | ≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
MDL | MFCD00866513 |
SMILES | C1=C(C2=C(N=CN=C2N1C3C(C(C(O3)CO)O)O)N)C#N |
InChIKey | XOKJUSAYZUAMGJ-WOUKDFQISA-N |
InChI | InChI=1S/C12H13N5O4/c13-1-5-2-17(11-7(5)10(14)15-4-16-11)12-9(20)8(19)6(3-18)21-12/h2,4,6,8-9,12,18-20H,3H2,(H2,14,15,16)/t6-,8-,9-,12-/m1/s1 |
PubChem CID | 11824 |
Target Point | XBP1;IRE1;Apoptosis;CDK |
Passage | ER Stress;Apoptosis;Cell Cycle |
Background | Toyocamycin is an inhibitor of XBP1. Toyocamycin affects the IRE1α-XBP1 pathway, inhibits the fracture of XBP1 mRNA, and does not affect the phosphorylation of IRE1α itself. Toyocamycin specifically inhibits CDK9. Toyocamycin can block RNA synthesis and ribosome function, and induce apoptosis. |
Biological Activity | Toyocamycin 是一种腺苷类似物,是一种 XBP1 抑制剂。Toyocamycin 可阻断 RNA 合成和核糖体功能,诱导细胞凋亡。Toyocamycin 影响 IRE1α-XBP1 通路,抑制 XBP1 mRNA 的裂解,IC50 值为 80 nM。Toyocamycin 能特异性抑制 CDK9,其 IC50 值为 79 nM。[1-3] |
IC50 | CDK9/cyclinT1: 9nM(IC50);CDK7/Mat1/cyclinH1: 2.8μM(IC50);CDK2/cyclinA: 0.67μM(IC50);Cdk4/cyclin D3: 15μM(IC50);cdk6/cyclin D3: >10μM(IC50) [1] |
Data Literature Source | [1]. Ri M,et al. Identification of Toyocamycin,an agent cytotoxic for multiple myeloma cells,as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012 Jul;2(7):e79. [2]. Pandey S,et al. Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. Cancers (Basel). 2022 Jul 8;14(14):3340. |
Unit | Bottle |
Specification | 2mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.